FR10C0006I2 - Agonistes du recepteur beta 2-adrenergique - Google Patents

Agonistes du recepteur beta 2-adrenergique

Info

Publication number
FR10C0006I2
FR10C0006I2 FR10C0006C FR10C0006C FR10C0006I2 FR 10C0006 I2 FR10C0006 I2 FR 10C0006I2 FR 10C0006 C FR10C0006 C FR 10C0006C FR 10C0006 C FR10C0006 C FR 10C0006C FR 10C0006 I2 FR10C0006 I2 FR 10C0006I2
Authority
FR
France
Prior art keywords
beta
receptor agonists
adrenergic receptor
adrenergic
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR10C0006C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10854788&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR10C0006(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Publication of FR10C0006I1 publication Critical patent/FR10C0006I1/fr
Application granted granted Critical
Publication of FR10C0006I2 publication Critical patent/FR10C0006I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
    • C07C215/80—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring containing at least two amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
FR10C0006C 1999-06-04 2010-02-15 Agonistes du recepteur beta 2-adrenergique Active FR10C0006I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9913083.3A GB9913083D0 (en) 1999-06-04 1999-06-04 Organic compounds
PCT/EP2000/005058 WO2000075114A1 (fr) 1999-06-04 2000-06-02 Agonistes du recepteur beta 2-adrenergique

Publications (2)

Publication Number Publication Date
FR10C0006I1 FR10C0006I1 (fr) 2010-03-26
FR10C0006I2 true FR10C0006I2 (fr) 2011-04-01

Family

ID=10854788

Family Applications (1)

Application Number Title Priority Date Filing Date
FR10C0006C Active FR10C0006I2 (fr) 1999-06-04 2010-02-15 Agonistes du recepteur beta 2-adrenergique

Country Status (38)

Country Link
US (9) US6878721B1 (fr)
EP (2) EP2332915B1 (fr)
JP (1) JP3785365B2 (fr)
KR (1) KR100718615B1 (fr)
CN (1) CN1156451C (fr)
AR (1) AR035548A1 (fr)
AT (1) ATE440083T1 (fr)
AU (1) AU765919B2 (fr)
BE (1) BE2010C011I2 (fr)
BR (1) BRPI0011324B8 (fr)
CA (1) CA2375810C (fr)
CO (1) CO5170518A1 (fr)
CY (3) CY1109604T1 (fr)
CZ (1) CZ302403B6 (fr)
DE (2) DE122010000009I2 (fr)
DK (2) DK1183240T3 (fr)
ES (2) ES2331457T3 (fr)
FR (1) FR10C0006I2 (fr)
GB (1) GB9913083D0 (fr)
HK (2) HK1045837B (fr)
HU (1) HU227034B1 (fr)
IL (2) IL146578A0 (fr)
LU (1) LU91651I2 (fr)
MX (1) MXPA01012474A (fr)
MY (1) MY126951A (fr)
NL (1) NL300437I1 (fr)
NO (2) NO322944B1 (fr)
NZ (1) NZ515669A (fr)
PE (1) PE20010219A1 (fr)
PL (1) PL198847B1 (fr)
PT (2) PT1183240E (fr)
RU (1) RU2244709C2 (fr)
SI (1) SI1183240T1 (fr)
SK (1) SK287260B6 (fr)
TR (1) TR200103497T2 (fr)
TW (1) TWI253447B (fr)
WO (1) WO2000075114A1 (fr)
ZA (1) ZA200109931B (fr)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
GB0121214D0 (en) * 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (fr) 2001-11-13 2003-05-22 Theravance, Inc. Agonistes de recepteur d'aryl aniline beta-2 adrenergique
EP2311818B1 (fr) 2002-02-28 2013-01-16 Novartis AG Combinaison d'un dérivé de 5-phenylthiazole utile comme inhibiteur de kinase PI3 et d'un composé antiinflammatoire, bronchodilatateur ou d'un antihistaminique.
US6933410B2 (en) * 2002-03-08 2005-08-23 Novartis Ag Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine
US7250426B2 (en) * 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
DE10256080A1 (de) * 2002-11-29 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropiumhaltige Arzneimittelkombination für die Inhalation
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
PE20100399A1 (es) * 2003-04-02 2010-06-01 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
GB0307856D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
MXPA05010712A (es) * 2003-04-04 2005-12-15 Novartis Ag Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
EP1574501A1 (fr) * 2004-03-11 2005-09-14 Pfizer Limited Dérivés de quinoléinone, compositions pharmaceutiques les contenant et leur usage
WO2005092861A1 (fr) * 2004-03-11 2005-10-06 Pfizer Limited Derives de quinolinone compositions pharmaceutiques contenant ces derives et utilisation de celles-ci
BRPI0509184A (pt) 2004-03-23 2007-09-18 Novartis Ag composições farmacêuticas
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds
US7566785B2 (en) * 2004-09-10 2009-07-28 Theravance, Inc. Amidine substituted aryl aniline compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
RU2442771C2 (ru) 2005-08-08 2012-02-20 Арджента Дискавери Лтд Производные бицикло[2,2,1]гепт-7-иламина и их применения
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
EP1922070A1 (fr) * 2005-08-26 2008-05-21 AstraZeneca AB Combinaison de composes convenant au traitement d'affections respiratoires, notamment la broncho-pneumopathie chronique obstructive (bpco) et l'asthme
AU2006303452B2 (en) 2005-10-21 2011-06-09 Novartis Ag Human antibodies against IL13 and therapeutic uses
TWI392493B (zh) * 2005-10-26 2013-04-11 Novartis Ag 格隆溴銨(GLYCOPYRROLATE)及β2腎上腺素受體激動劑之組合
GB0525671D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
DK2013211T3 (da) 2006-04-21 2012-07-02 Novartis Ag Purinderivater til anvendelse som adenosin-A2A-receptoragonister
ES2396987T3 (es) 2006-06-30 2013-03-01 Novartis Ag Derivados de quinolina y sus composiciones farmacéuticas
EP1878722A1 (fr) * 2006-07-13 2008-01-16 Novartis AG Dérivés de quinolinone et leur compositions pharmaceutiques
EP1914227A1 (fr) * 2006-08-31 2008-04-23 Novartis AG Forme crystalline polymorphe d'une dérivé de indan-2-ylamino-hydroxyethyl-quinolinone maleate comme agoniste de 2-adrénorécepteur beta
EP2081933B1 (fr) 2006-09-29 2011-03-23 Novartis AG PYRAZOLOPYRIMIDINES UTILISÉES COMME INHIBITEURS DES LIPIDES KINASES Pl3K
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
PL2104535T3 (pl) 2007-01-10 2011-05-31 Irm Llc Związki i kompozycje jako inhibitory proteazy aktywujące kanały
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
CN101646437A (zh) 2007-02-09 2010-02-10 Irm责任有限公司 作为通道活化蛋白酶抑制剂的化合物和组合物
EA200901489A1 (ru) 2007-05-07 2010-04-30 Новартис Аг Органические соединения
AU2008334629B2 (en) 2007-12-10 2012-04-12 Novartis Ag Organic compounds
ES2442930T3 (es) 2008-01-11 2014-02-14 Novartis Ag Pirimidinas como inhibidores de cinasas
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
AU2009260899B2 (en) 2008-06-18 2012-02-23 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
EA019441B1 (ru) 2008-12-30 2014-03-31 Палмаджен Терепьютикс (Инфлеммейшн) Лимитед Сульфонамиды, предназначенные для лечения респираторных нарушений
DK2391366T3 (da) 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
TW201040154A (en) * 2009-02-13 2010-11-16 Sanofi Aventis Novel substituted indanes, process for preparation thereof and use thereof as a medicament
WO2010150014A1 (fr) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (fr) 2009-08-12 2011-02-17 Novartis Ag Composés hydrazone hétérocycliques et leurs utilisations pour traiter le cancer et l'inflammation
AU2010284254B2 (en) 2009-08-17 2015-09-17 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2011020861A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composés d'oximes hétérocycliques
US20110098311A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorported Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011056929A1 (fr) * 2009-11-04 2011-05-12 Massachusetts Institute Of Technology Synthèse en flux continu d'alcools aminés à l'aide de microréacteurs
WO2011098746A1 (fr) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2011102794A1 (fr) * 2010-02-18 2011-08-25 Astrazeneca Ab Procédés de fabrication de dérivés cyclopropyl-amides et intermédiaires associés à la fabrication de ceux-ci
US8680303B2 (en) 2010-03-01 2014-03-25 Massachusetts Institute Of Technology Epoxidation catalysts
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
LT2593452T (lt) 2010-07-14 2017-04-10 Novartis Ag Heterocikliniai junginiai, kaip ip receptoriaus agonistai
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
KR20180028563A (ko) 2010-10-12 2018-03-16 시플라 리미티드 약학 조성물
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
EP2673277A1 (fr) 2011-02-10 2013-12-18 Novartis AG Composés de [1, 2, 4]triazolo [4, 3 -b]pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
EP2678338B1 (fr) 2011-02-25 2015-09-09 Novartis AG Composés et compositions en tant qu'inhibiteurs de trk
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
EP2755976B1 (fr) 2011-09-15 2018-07-18 Novartis AG 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituées en position 6 à activité tyrosine kinase
WO2013038381A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés d'amide pyridine/pyrazine
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
WO2013038378A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyridinamides
WO2013038373A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyrimidinamides
EP2755967B1 (fr) 2011-09-16 2015-10-21 Novartis AG Composés hétérocycliques destinés au traitement de la mucosviscidose
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
EP2802581A1 (fr) 2012-01-13 2014-11-19 Novartis AG 7,8-dihydropyrido[3,4-b]pyrazines utilisées comme agonistes du récepteur ip pour le traitement de l'hypertension artérielle pulmonaire (htap) et des troubles associés
AR089698A1 (es) 2012-01-13 2014-09-10 Novartis Ag Compuestos heterociclicos antagonistas del receptor ip
WO2013105063A1 (fr) 2012-01-13 2013-07-18 Novartis Ag Pipéridines condensées utilisées comme agonistes du récepteur ip pour le traitement de l'hypertension artérielle pulmonaire (htap) et de troubles associés
WO2013105065A1 (fr) 2012-01-13 2013-07-18 Novartis Ag Pipéridines condensées utilisées comme agonistes du récepteur ip pour le traitement de l'htap et de troubles connexes
WO2013105061A1 (fr) 2012-01-13 2013-07-18 Novartis Ag Dihydropyrido [2,3-b]pyrazines fusionnées comme agonistes des récepteurs ip pour le traitement de l'hypertension artérielle pulmonaire (hap) et des troubles connexes
JP6058698B2 (ja) 2012-01-13 2017-01-11 ノバルティス アーゲー Ｉｐ受容体アゴニストの塩
WO2013132514A2 (fr) * 2012-03-09 2013-09-12 Rao Davuluri Ramamohan Nouveau procédé de préparation de (r)-5-[2-[(5, 6-diéthyl-2, 3-dihydro-1h-indèn-2-yl) amino]-1-hydroxyéthyl]-8-hydroxy quinoléin-2(1h)-one
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP2834246B1 (fr) 2012-04-03 2021-07-28 Novartis AG Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
CN104379566B (zh) * 2012-07-11 2016-08-24 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
WO2014008639A1 (fr) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 Procédé de préparation d'indacatérol
CN103539677B (zh) * 2012-07-16 2015-04-22 武汉万知生物医药有限公司 一种5,6-二乙基-2,3-二氢-1h-茚-2-胺盐酸盐的制备方法
EP3138837B1 (fr) 2012-09-21 2021-11-24 Crystal Pharma, S.A.U. Base libre d'indacatérol sous forme solide
WO2014044288A1 (fr) * 2012-09-21 2014-03-27 Crystal Pharma Sa Procédés de préparation d'indacatérol et de ses sels pharmaceutiquement acceptables
JP6363616B2 (ja) 2012-12-19 2018-07-25 ノバルティス アーゲー オートタキシン阻害剤
WO2014108449A1 (fr) 2013-01-08 2014-07-17 Atrogi Ab Procédé de criblage, trousse, méthode de traitement et composé destinés à être utilisé dans une méthode de traitement
CN105189500A (zh) 2013-02-13 2015-12-23 诺华股份有限公司 Ip受体激动剂杂环化合物
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
AU2014229361B2 (en) 2013-03-14 2016-08-04 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
EP2968340A4 (fr) 2013-03-15 2016-08-10 Intellikine Llc Combinaison d'inhibiteurs de kinase et ses utilisations
CZ306252B6 (cs) 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
WO2014154841A1 (fr) * 2013-03-27 2014-10-02 Laboratorios Lesvi, S.L. Procédé pour la fabrication de (r)-5-[2-(5,6-diéthyl-indan-2-ylamino)-1-hydroxyéthyl]-8-hydroxy-(1h)-quinolin-2-one
EP3022202B1 (fr) 2013-07-18 2019-05-15 Novartis AG Inhibiteurs de l'autotaxine comprennant un motif anneau hétéroaromatique-benzyle-amide-cycle
WO2015008229A1 (fr) 2013-07-18 2015-01-22 Novartis Ag Inhibiteurs de l'autotaxine
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
CN104744360B (zh) * 2013-12-26 2017-02-22 成都伊诺达博医药科技有限公司 一种合成茚达特罗的新方法
PL3092217T3 (pl) 2014-01-09 2020-11-16 Davuluri, Ramamohan Rao Nowy sposób wytwarzania indakaterolu lub jego farmaceutycznie dopuszczalnych soli
CN103830195A (zh) * 2014-03-11 2014-06-04 熊妲妮 一种茚达特罗片及其制备方法
CN103830193A (zh) * 2014-03-11 2014-06-04 熊妲妮 茚达特罗片制剂及其制备方法
CA2940599A1 (fr) 2014-03-27 2015-10-01 Novartis Ag Dispersions d'huile-dans-l'eau solides sechees par pulverisation pour l'inhalation de principes pharmaceutiques actifs
EP3134398A1 (fr) 2014-04-24 2017-03-01 Novartis Ag Inhibiteurs de l'autotaxine
CA2945069A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Derives amines de pyridine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
PL3134395T3 (pl) 2014-04-24 2018-07-31 Novartis Ag Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
JP6433509B2 (ja) 2014-04-24 2018-12-05 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピラジン誘導体
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
EP3174869B1 (fr) 2014-07-31 2020-08-19 Novartis AG Polythérapie avec un inhibiteur de met et un inhibiteur d'egfr
DE102014217201A1 (de) 2014-08-28 2016-03-03 Henkel Ag & Co. Kgaa Verwendung einer Kombination von Rheolate FX 1100 und Luviskol K90
DE102014217205A1 (de) 2014-08-28 2016-03-03 Henkel Ag & Co. Kgaa Verwendung einer Kombination von Rheolate FX 1100 und Luviskol VA 64 W
ES2758677T3 (es) * 2015-01-20 2020-05-06 Olon Spa Procedimiento para la preparación de derivados de indanamina y nuevos compuestos intermedios de síntesis
AU2016209930A1 (en) 2015-01-20 2017-07-13 Novartis Ag Application unlock using a connected physical device and transfer of data therebetween
CN107531636B (zh) * 2015-04-09 2022-11-25 正大天晴药业集团股份有限公司 茚达特罗或其盐的制备方法
PL3111978T3 (pl) 2015-07-03 2022-01-24 Novartis Ag Inhalator przystosowany do odczytu informacji przechowywanych w środkach przechowywania danych pojemnika
ITUB20153978A1 (it) * 2015-09-28 2017-03-28 Laboratorio Chimico Int S P A Procedimento per la preparazione di derivati di indanammina e di nuovi intermedi di sintesi.
CN105884626B (zh) * 2016-05-04 2017-10-20 龙曦宁（上海）医药科技有限公司 一种2‑氨基茚满衍生物的合成方法及其产品
CN108101841B (zh) * 2016-11-24 2021-04-06 江苏恒瑞医药股份有限公司 一种制备茚达特罗或其盐的方法
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
WO2019135101A1 (fr) 2018-01-02 2019-07-11 Deva Holding Anonim Sirketi Procédé de préparation de 5-(1-hydroxyéthyle à substitution amino en position 2)-quinoléine-2(1h)-one à substitution oxy en position 8
WO2019182721A1 (fr) 2018-03-19 2019-09-26 Dow Silicones Corporation Copolymère séquencé de polyoléfine-polydiorganosiloxane et procédé de réaction d'hydrosilylaton pour sa synthèse
CA3093558A1 (fr) 2018-03-19 2019-09-26 Dow Silicones Corporation Compositions adhesives thermofusibles a base de polyorganosiloxane contenant des copolymeres de polyolefine-polydiorganosiloxanes et leurs procedes de preparation et d'utilisation
JP2021518460A (ja) 2018-03-19 2021-08-02 ダウ シリコーンズ コーポレーション ポリオレフィン−ポリジオルガノシロキサンコポリマーを含有するホットメルト接着剤組成物ならびにその調製方法および使用方法
JP7334195B2 (ja) 2018-07-17 2023-08-28 ダウ シリコーンズ コーポレーション ポリシロキサン樹脂－ポリオレフィンコポリマー並びにその調製方法及び使用方法
WO2020047225A1 (fr) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Procédés de traitement de bronchopneumopathie chronique obstructive
MX2021003819A (es) 2018-10-05 2021-06-23 Vertex Pharma Moduladores de alfa-1 antitripsina.
CN109369417B (zh) * 2018-10-19 2021-07-06 诚达药业股份有限公司 一种2-氨基茚满衍生物的制备方法
US20200163955A1 (en) 2018-11-22 2020-05-28 Glenmark Specialty S.A. Sterile compositions of indacaterol suitable for nebulization
WO2020141472A1 (fr) 2019-01-03 2020-07-09 Glenmark Specialty S.A. Composition de nébulisation comprenant du tiotropium et de l'indacatérol
CN109896967B (zh) * 2019-04-04 2021-10-22 上海工程技术大学 一种间二乙氨基苯酚的制备方法
CN109896966B (zh) * 2019-04-04 2021-10-22 上海工程技术大学 一种n,n-二丁基间氨基苯酚的制备方法
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
CN110229078A (zh) * 2019-05-22 2019-09-13 博诺康源(北京)药业科技有限公司 一种茚达特罗起始原料开环杂质的制备
AU2020290094B2 (en) 2019-06-10 2024-01-18 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
PE20220346A1 (es) 2019-08-28 2022-03-14 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
AU2021246527A1 (en) * 2020-04-03 2022-10-27 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
AU2021325431B2 (en) 2020-08-14 2024-01-18 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
TW202228690A (zh) 2020-09-29 2022-08-01 美商艾法瑪實驗室公司 茚達特羅(indacaterol)之液體調配物
CN115677577A (zh) * 2021-11-03 2023-02-03 中国药科大学 靶向srsf6蛋白的小分子化合物及其制备方法和用途
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
CN115521254A (zh) * 2022-09-27 2022-12-27 中国药科大学 一种茚达特罗衍生物及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8707123D0 (en) 1987-03-25 1987-04-29 Pfizer Ltd Antiarrhythmic agents
ZA903906B (en) * 1989-05-25 1992-02-26 Takeda Chemical Industries Ltd Benzocycloalkane derivatives and production thereof
AU632809B2 (en) 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
GB9107827D0 (en) 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
JPH0518007A (ja) 1991-07-05 1993-01-26 Konoike Constr Ltd 鉄骨梁との接合部を内蔵したｐｃ柱
IL104567A (en) * 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO1993018007A1 (fr) * 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Nouveau derive de carbostyrile
DK0608568T3 (da) * 1993-01-29 1998-09-28 American Cyanamid Co Aminocycloalkanobenzodioxoler som beta 3-selektiveadrenerge midler
DE69422044T2 (de) * 1993-08-06 2000-05-31 Upjohn Co 2-aminoindane als selektive dopamin-d3-liganden
FR2711407B1 (fr) * 1993-10-19 1996-01-26 Allevard Sa Perfectionnements aux barres de torsion métalliques.
US5578638A (en) 1993-11-05 1996-11-26 American Cyanamid Company Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
RU2161601C2 (ru) 1995-02-01 2001-01-10 Фармация Энд Апджон Компани 2-аминоинданы в качестве селективных лигандов допамина д3
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
TW375604B (en) 1996-02-19 1999-12-01 Kissei Pharmaceutical 3,4-di-substituting phenyl-ethanolamine-tetrahydronaphthyl carboxylic amide derivatives
JP3708624B2 (ja) 1996-03-27 2005-10-19 キッセイ薬品工業株式会社 ３，４−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体
JP3690071B2 (ja) 1997-06-24 2005-08-31 井関農機株式会社 ロータリ耕耘具の防護装置
AU8562098A (en) 1997-08-19 1999-03-08 Kissei Pharmaceutical Co. Ltd. Phenylethanolaminotetralin derivatives and bronchodilators
ATE423555T1 (de) * 1998-04-06 2009-03-15 Astellas Pharma Inc Verwendung von beta-3-adrenergen-rezeptoren agonisten in der behandlung von dysurie
SI1300407T2 (sl) 2000-06-27 2011-09-30 S A L V A T Lab Sa Karbamati, izvedeni iz arilalkilaminov

Also Published As

Publication number Publication date
AU765919B2 (en) 2003-10-02
WO2000075114A1 (fr) 2000-12-14
BRPI0011324B8 (pt) 2021-05-25
NO20015912L (no) 2002-01-21
AU5074500A (en) 2000-12-28
EP1183240A1 (fr) 2002-03-06
US9040559B2 (en) 2015-05-26
CY1109604T1 (el) 2012-01-25
US20130231367A1 (en) 2013-09-05
ES2402535T3 (es) 2013-05-06
LU91651I9 (fr) 2019-01-03
US20100029705A1 (en) 2010-02-04
CY2010003I1 (el) 2012-01-25
PE20010219A1 (es) 2001-03-21
NO322944B1 (no) 2006-12-18
RU2244709C2 (ru) 2005-01-20
ZA200109931B (en) 2002-06-05
BR0011324A (pt) 2002-03-05
HU227034B1 (en) 2010-05-28
CN1156451C (zh) 2004-07-07
ES2331457T3 (es) 2010-01-05
DE122010000009I2 (de) 2012-08-09
US8436017B2 (en) 2013-05-07
EP1183240B1 (fr) 2009-08-19
US20120302531A1 (en) 2012-11-29
HUP0201658A3 (en) 2005-01-28
JP3785365B2 (ja) 2006-06-14
US7820694B2 (en) 2010-10-26
NO2010014I1 (no) 2010-07-26
CZ302403B6 (cs) 2011-05-04
CY2010003I2 (el) 2012-01-25
DE122010000009I1 (de) 2010-07-01
MY126951A (en) 2006-11-30
HK1154584A1 (en) 2012-04-27
BE2010C011I2 (fr) 2019-05-21
NO2010014I2 (fr) 2011-10-17
PL198847B1 (pl) 2008-07-31
SK287260B6 (sk) 2010-04-07
NZ515669A (en) 2004-01-30
PT2332915E (pt) 2013-04-11
US20120077838A1 (en) 2012-03-29
KR20020012590A (ko) 2002-02-16
CA2375810A1 (fr) 2000-12-14
TWI253447B (en) 2006-04-21
SI1183240T1 (sl) 2010-01-29
US20050153957A1 (en) 2005-07-14
US8658673B2 (en) 2014-02-25
CZ20014301A3 (cs) 2002-03-13
FR10C0006I1 (fr) 2010-03-26
TR200103497T2 (tr) 2002-05-21
US6878721B1 (en) 2005-04-12
PT1183240E (pt) 2009-11-03
LU91651I2 (fr) 2010-04-19
US8283362B2 (en) 2012-10-09
SK17432001A3 (sk) 2002-06-04
EP2332915B1 (fr) 2013-02-27
AR035548A1 (es) 2004-06-16
KR100718615B1 (ko) 2007-05-16
NO20015912D0 (no) 2001-12-03
GB9913083D0 (en) 1999-08-04
US20110034509A1 (en) 2011-02-10
PL352100A1 (en) 2003-07-28
DE60042781D1 (de) 2009-10-01
HUP0201658A2 (en) 2002-08-28
US20140343091A1 (en) 2014-11-20
CO5170518A1 (es) 2002-06-27
EP2332915A1 (fr) 2011-06-15
CN1353692A (zh) 2002-06-12
CA2375810C (fr) 2010-09-07
ATE440083T1 (de) 2009-09-15
CY1114120T1 (el) 2016-07-27
HK1045837A1 (en) 2002-12-13
BR0011324B1 (pt) 2014-11-25
US7622483B2 (en) 2009-11-24
US8067437B2 (en) 2011-11-29
JP2003501417A (ja) 2003-01-14
DK1183240T3 (da) 2009-11-23
IL146578A0 (en) 2002-07-25
US8796307B2 (en) 2014-08-05
IL146578A (en) 2007-05-15
MXPA01012474A (es) 2002-06-04
HK1045837B (zh) 2010-03-26
NL300437I1 (nl) 2010-04-01
DK2332915T3 (da) 2013-05-27
US20140066478A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
FR10C0006I2 (fr) Agonistes du recepteur beta 2-adrenergique
ATE302748T1 (de) Beta 2- adrenergische rezeptoragonisten
FR11C0004I2 (fr) Agonistes du recepteur a 2a n-pyrazole
PT1192169E (pt) C-pirazoles agonistas do receptor a2a
MA25403A1 (fr) Ligandes de recepteur de melanocortine
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
DE69800895D1 (de) Interleukin-1 Rezeptor Antagonist beta (il-1rabeta)
NO20015015D0 (no) Östrogenreseptor-beta-ligander
ATE240342T1 (de) Propargylphenyl-äther a2a rezeptoragonisten
ITMI20000606A0 (it) Dispositivo per il collegamento di due parti costruttive
DK1146874T3 (da) Vitronectinreceptoragonist
NO20016052D0 (no) IL-8-reseptor-antagonister
DE60033145D1 (de) Il-8 rezeptorantagonist
NO20015774L (no) IL-8 reseptorantagonister
HK1048803A1 (en) β 2-ADRENERGIC RECEPTOR AGONISTS
SI1235787T1 (en) $g(b)2-ADRENERGIC RECEPTOR AGONISTS
SI1019075T1 (sl) Beta 2-adrenergicni receptorski agonisti